Lead Product(s) : Rocatinlimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Kyowa Reveals Top-Line Data from Rocatinlimab Phase 3 ROCKET HORIZON for Atopic Dermatitis
Details : KHK4083 (rocatinlimab) is an anti-OX40 mAb that inhibits and reduces the number of OX40+ pathogenic T cells responsible for driving systemic and local atopic dermatitis inflammatory responses.
Product Name : KHK4083
Product Type : Antibody
Upfront Cash : Inapplicable
September 25, 2024
Lead Product(s) : Rocatinlimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Galderma
Deal Size : Inapplicable
Deal Type : Inapplicable
Galderma Announces Updates on Nemolizumab Development
Details : CD14152 (nemolizumab) is an anti-IL-31 receptor antibody under study for prurigo nodularis and moderate to severe atopic dermatitis.
Product Name : CD14152
Product Type : Antibody
Upfront Cash : Inapplicable
February 15, 2024
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Galderma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rocatinlimab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AMG451 (rocatinlimab) an investigational, is a potential first-in-class, anti-OX40 monoclonal antibody that inhibits and reduces the number of OX40+ pathogenic T cells responsible for driving systemic and local atopic dermatitis inflammatory responses.
Product Name : KHK4083
Product Type : Antibody
Upfront Cash : Inapplicable
March 17, 2023
Lead Product(s) : Rocatinlimab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Galderma Announces Updates on Nemolizumab Development
Details : CD14152 (nemolizumab) is a human mAb that blocks the α subunit of the IL-31 receptor, modulates the neuroimmune response, and rapidly alleviates itching by directly blocking signaling. It is being investigated for moderate-to-severe atopic dermatitis.
Product Name : CD14152
Product Type : Antibody
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Biocon Biologics Out-Licenses Two Biosimilar Assets to Yoshindo for Commercialization in Japan
Details : Ustekinumab, a biosimilar of Stelara, is a monoclonal antibody used to treat several autoimmune conditions and Denosumab, a biosimilar referencing Prolia®, is a monoclonal antibody for the treatment of osteoporosis.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
October 17, 2022
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Biocon
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Galderma
Deal Size : Inapplicable
Deal Type : Inapplicable
Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
Details : Patients treated with CD14152 (nemolizumab) monotherapy (without background topical corticosteroids or topical calcineurin inhibitors) showed clinically and statistically significant improvement in both primary endpoints compared to placebo after 16 week...
Product Name : CD14152
Product Type : Antibody
Upfront Cash : Inapplicable
June 22, 2022
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Galderma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Intas Enters License Agreement with Meiji and Dong Commercialize DMB-3115
Details : Under the terms of the agreement, Intas was granted the exclusive license rights to market DMB-3115 worldwide, excluding Japan, Korea and certain countries in Asia.
Product Name : DMB-3115
Product Type : Antibody
Upfront Cash : Undisclosed
July 21, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Intas Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Dong-A Socio Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable
Meiji Seika Pharma: Promising Results of Phase I Clinical Trial of DMB-3115
Details : A single subcutaneous injection of DMB3115 in healthy volunteers was well tolerated. The reported adverse events corresponded with the known safety profile of ustekinumab.
Product Name : DMB-3115
Product Type : Antibody
Upfront Cash : Inapplicable
May 21, 2021
Lead Product(s) : Ustekinumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Dong-A Socio Holdings
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Medimetriks Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difamilast is a topical atopic dermatitis drug candidate discovered by Otsuka that has phosphodiesterase 4 (PDE4) inhibitory activity.
Product Name : Moizerto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 28, 2020
Lead Product(s) : Difamilast
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Medimetriks Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nemolizumab is an anti-interleukin-31 (IL-31) receptor A humanized monoclonal antibody created by Chugai.
Product Name : CD14152
Product Type : Antibody
Upfront Cash : Inapplicable
September 07, 2020
Lead Product(s) : Nemolizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable